MA37649B1 - Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées - Google Patents

Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées

Info

Publication number
MA37649B1
MA37649B1 MA37649A MA37649A MA37649B1 MA 37649 B1 MA37649 B1 MA 37649B1 MA 37649 A MA37649 A MA 37649A MA 37649 A MA37649 A MA 37649A MA 37649 B1 MA37649 B1 MA 37649B1
Authority
MA
Morocco
Prior art keywords
producing hydroxylated
compounds
cyclopenta
cyclopentylpyrimidine compounds
hydroxylated cyclopentylpyrimidine
Prior art date
Application number
MA37649A
Other languages
English (en)
French (fr)
Other versions
MA37649A1 (fr
Inventor
Travis Remarchuk
Jonathan W Lane
Sagar Shakya
Keith L Spencer
Peter J Stengel
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Publication of MA37649A1 publication Critical patent/MA37649A1/fr
Publication of MA37649B1 publication Critical patent/MA37649B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA37649A 2012-05-17 2013-05-17 Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées MA37649B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648421P 2012-05-17 2012-05-17
US201361785281P 2013-03-14 2013-03-14
PCT/US2013/041624 WO2013173736A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (2)

Publication Number Publication Date
MA37649A1 MA37649A1 (fr) 2016-06-30
MA37649B1 true MA37649B1 (fr) 2017-03-31

Family

ID=48534507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37649A MA37649B1 (fr) 2012-05-17 2013-05-17 Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées

Country Status (18)

Country Link
US (1) US9309204B2 (https=)
EP (1) EP2861583B1 (https=)
JP (1) JP6214636B2 (https=)
KR (1) KR20150020211A (https=)
CN (1) CN104487430B (https=)
AU (1) AU2013262568B2 (https=)
BR (1) BR112014028570A2 (https=)
CA (1) CA2873653A1 (https=)
DK (1) DK2861583T3 (https=)
ES (1) ES2588878T3 (https=)
IL (1) IL235714A0 (https=)
MA (1) MA37649B1 (https=)
MX (1) MX2014013865A (https=)
PL (1) PL2861583T3 (https=)
RU (1) RU2014151017A (https=)
SG (1) SG11201407613RA (https=)
SI (1) SI2861583T1 (https=)
WO (1) WO2013173736A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350443B (es) 2012-05-17 2017-09-06 Genentech Inc Proceso para hacer compuestos de aminoácidos.
CN104471070B (zh) 2012-05-17 2018-09-25 基因泰克公司 制备羟基化环戊并嘧啶化合物和其盐的方法
HRP20200992T1 (hr) 2012-05-17 2020-10-16 Genentech, Inc. Amorfni oblik pirimidinil-ciklopentanskog spoja koji inhibira akt, te njegovi pripravci i postupci
AU2013262505B2 (en) 2012-05-17 2017-09-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
ES2765511T3 (es) 2013-11-15 2020-06-09 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano
SG11201601813UA (en) * 2013-11-27 2016-04-28 Sunshine Lake Pharma Co Ltd Processes for preparing dihydropyrimidine derivatives and intermediates thereof
ES2749100T3 (es) * 2014-09-26 2020-03-19 Hoffmann La Roche Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina
IL295929A (en) 2020-06-16 2022-10-01 Hoffmann La Roche Process for making hydroxylated cyclopentylpyrimidine compounds
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506369A (ja) 1993-12-12 1997-06-24 アグロジーン・リミテッド 菌類感染から植物を保護するための新規方法
AU724216B2 (en) 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
CA2363169A1 (en) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CN1178931C (zh) * 1999-06-03 2004-12-08 帝国脏器制药株式会社 取代吡唑化合物
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
JP4550811B2 (ja) 2003-06-09 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング パピローマウイルスのインヒビター
CA2546754A1 (en) 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP5157576B2 (ja) 2007-05-14 2013-03-06 住友化学株式会社 光学活性2−アルキル−1,1,3−トリアルコキシカルボニルプロパンの製造方法
CN101918373B (zh) * 2007-07-05 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
EP2209775A1 (en) 2007-10-09 2010-07-28 UCB Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
NZ586346A (en) * 2008-01-09 2012-02-24 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
AU2009303475B2 (en) * 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
CN102459165B (zh) 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
MX2012004780A (es) 2009-10-23 2012-08-23 Lilly Co Eli Inhibidores de akt.
EP2592933B1 (en) 2010-07-16 2017-04-05 Anderson Gaweco Mif inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
CN104471070B (zh) 2012-05-17 2018-09-25 基因泰克公司 制备羟基化环戊并嘧啶化合物和其盐的方法
AU2013262505B2 (en) 2012-05-17 2017-09-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
MX350443B (es) 2012-05-17 2017-09-06 Genentech Inc Proceso para hacer compuestos de aminoácidos.
WO2014071194A2 (en) 2012-11-01 2014-05-08 Katz Robert S Methods for treating fibromyalgia
WO2014127350A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
WO2014150395A1 (en) 2013-03-15 2014-09-25 Shifa Biomedical Corporation Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Also Published As

Publication number Publication date
CA2873653A1 (en) 2013-11-21
JP6214636B2 (ja) 2017-10-18
MX2014013865A (es) 2015-05-07
EP2861583A1 (en) 2015-04-22
CN104487430A (zh) 2015-04-01
US20150099881A1 (en) 2015-04-09
AU2013262568A1 (en) 2015-01-22
RU2014151017A (ru) 2016-07-10
SG11201407613RA (en) 2015-01-29
IL235714A0 (en) 2015-02-01
PL2861583T3 (pl) 2016-12-30
KR20150020211A (ko) 2015-02-25
AU2013262568B2 (en) 2017-08-31
HK1208673A1 (en) 2016-03-11
EP2861583B1 (en) 2016-06-29
MA37649A1 (fr) 2016-06-30
WO2013173736A1 (en) 2013-11-21
US9309204B2 (en) 2016-04-12
DK2861583T3 (en) 2016-10-03
CN104487430B (zh) 2016-08-24
SI2861583T1 (sl) 2016-10-28
JP2015518837A (ja) 2015-07-06
ES2588878T3 (es) 2016-11-07
BR112014028570A2 (pt) 2018-04-24

Similar Documents

Publication Publication Date Title
MA37649B1 (fr) Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées
MA37647A1 (fr) Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci
UA111854C2 (uk) Способи і проміжні сполуки для отримання інгібіторів jak
JOP20190230A1 (ar) طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
MY196260A (en) Small Molecule Inhibitors of the Jak Family Of Kinases
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
MY161416A (en) 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors
NZ612909A (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
MX370390B (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MY200590A (en) Compounds useful as kinase inhibitors
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
MX2017016772A (es) Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo.
ATE474835T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2010147898A3 (en) Small molecule inhibitors of spleen tyrosine kinase (syk)
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MY196185A (en) Salts of a Pim Kinase Inhibitor
MA37751A1 (fr) Procédé de préparation de composés d'acides aminés
NZ586720A (en) Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
MX2010006331A (es) Hidantoinas sustituidas como inhibidores de cinasa mek.
MA50430B1 (fr) Composés d'imidazo[4,5-d]pyrrolo[2,3-b]pyridine comme inhibiteurs de janus kinases